About: uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Sector: Healthcare
Industry: Biotechnology
Latest price: $24.97 (+2.84%)
QURE NASDAQ Uniqure NV
Uniqure NV share price
Atividade de preço de QURE
Último preço
$ 25,300
Variação (24h)
0,33 USD (1,32%)
Volume
1.71M
Volume (média 4 sem.)
-
Abertura
$ 24,86
Variação do dia
$ 24,60 - $ 25,99
Fechamento anterior
$ 24,97
Último negócio
29 Oct, 8:21 pm GMT+0
Atrasado
29 Oct, 8:21 pm GMT+0
QURE price performance
Atrasado
29 Oct, 8:21 pm GMT+0
quote.marketSignals